tbuckley/cabot-search huggingface dataset:
Immunovirotherapy with measles virus strains in combination with anti–PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment
Authors: Jayson Hardcastle, Lisa Mills, Courtney S. Malo, Fang Jin, Cheyne Kurokawa, Hirosha Geekiyanage, Mark Schroeder, Jann Sarkaria, Aaron J. Johnson, Evanthia Galanis
Journal: Neuro-Oncology (2016)

Glioblastoma (GBM) is the most common primary malignant brain tumor and has a dismal prognosis. Measles virus (MV) therapy of GBM is a promising strategy due to preclinical efficacy, excellent clinical safety, and its ability to evoke antitumor pro-inflammatory responses. We hypothesized that combining anti– programmed cell death protein 1 (anti-PD-1) blockade and MV therapy can overcome immunosuppression and enhance immune effector cell responses against GBM, thus improving therapeutic outcome. In vitro assays of MV infection of glioma cells and infected glioma cells with mouse microglia ± aPD-1 blockade were established to assess damage associated molecular pattern (DAMP) molecule production, migration, and pro-inflammatory effects. C57BL/6 or athymic mice bearing syngeneic orthotopic GL261 gliomas were treated with MV, aPD-1, and combination treatment. T2* weighted immune cell-specific MRI and fluorescence activated cell sorting (FACS) analysis of treated mouse brains was used to examine adaptive immune responses following therapy. In vitro, MV infection induced human GBM cell secretion of DAMP (high-mobility group protein 1, heat shock protein 90) and upregulated programmed cell death ligand 1 (PD-L1). MV infection of GL261 murine glioma cells resulted in a pro-inflammatory response and increased migration of BV2 microglia. In vivo, MV+aPD-1 therapy synergistically enhanced survival of C57BL/6 mice bearing syngeneic orthotopic GL261 gliomas. MRI showed increased inflammatory cell influx into the brains of mice treated with MV+aPD-1; FACS analysis confirmed increased T-cell influx predominantly consisting of activated CD8+ T cells. This report demonstrates that oncolytic measles virotherapy in combination with aPD-1 blockade significantly improves survival outcome in a syngeneic GBM model and supports the potential of clinical/translational strategies combining MV with αPD-1 therapy in GBM treatment.
18 F-FDG-PET/CTA of Prosthetic Cardiac Valves and Valve-Tube Grafts
Authors: María N. Pizzi, Albert Roque, Hug Cuéllar-Calabria, Nuria Fernández-Hidalgo, Ignacio Ferreira-González, María T. González-Alujas, Alberto Igual-Barceló, David Garcia-Dorado, Benito Almirante, Joan Castell-Conesa, Manuel Escobar Amores, Pilar Tornos, Santiago Aguadé-Bruix
Journal: JACC. Cardiovascular imaging (2016)
Phase I-II Trial of Oral Cyclophosphamide, Prednisone and Lenalidomide (Revlimid®) (CPR) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma.
Authors: Donna E. Reece, Esther Masih-Khan, Arooj Khan, Peter Anglin, Christine Chen, Vishal Kukreti, Joseph R. Mikhael, Suzanne Trudel
Journal: Blood (2008)
Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update
Authors: Abram Recht, Elizabeth A. Comen, Richard E. Fine, Gini F. Fleming, Patricia H. Hardenbergh, Alice Y. Ho, Clifford A. Hudis, E. Shelley Hwang, Jeffrey J. Kirshner, Monica Morrow, Kilian E. Salerno, George W. Sledge, Lawrence J. Solin, Patricia A. Spears, Timothy J. Whelan, Mark R. Somerfield, Stephen B. Edge
Journal: Journal of Clinical Oncology (2016)

Purpose A joint American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology panel convened to develop a focused update of the American Society of Clinical Oncology guideline concerning use of postmastectomy radiotherapy (PMRT). Methods A recent systematic literature review by Cancer Care Ontario provided the primary evidentiary basis. The joint panel also reviewed targeted literature searches to identify new, potentially practice-changing data. Recommendations The panel unanimously agreed that available evidence shows that PMRT reduces the risks of locoregional failure (LRF), any recurrence, and breast cancer mortality for patients with T1-2 breast cancer with one to three positive axillary nodes. However, some subsets of these patients are likely to have such a low risk of LRF that the absolute benefit of PMRT is outweighed by its potential toxicities. In addition, the acceptable ratio of benefit to toxicity varies among patients and physicians. Thus, the decision to recommend PMRT requires a great deal of clinical judgment. The panel agreed clinicians making such recommendations for individual patients should consider factors that may decrease the risk of LRF, attenuate the benefit of reduced breast cancer-specific mortality, and/or increase risk of complications resulting from PMRT. When clinicians and patients elect to omit axillary dissection after a positive sentinel node biopsy, the panel recommends that these patients receive PMRT only if there is already sufficient information to justify its use without needing to know additional axillary nodes are involved. Patients with axillary nodal involvement after neoadjuvant systemic therapy should receive PMRT. The panel recommends treatment generally be administered to both the internal mammary nodes and the supraclavicular-axillary apical nodes in addition to the chest wall or reconstructed breast.
Parameters Associated with Treatment Failure with Direct Acting Antivirals against the Hepatitis C Virus (HCV) – Results Fro the German Hepatitis C Cohort (GECCO)
Authors: P. Ingiliz, S. Christensen, T. Kimhofer, D. Hueppe, K. Schewe, T. Lutz, C. Boesecke, K.-G. Simon, A. Baumgarten, S. Mauss
Journal: Journal of Hepatology (2016)
RIP3 Regulates Acute Cholestasis-Associated Necroptotic Signaling and Cell Death
Authors: M.B. Afonso, P.M. Rodrigues, A.L. Simão, H. Cortez-Pinto, D. Ofengeim, J.D. Amaral, R.E. Castro, J. Yuan, C.M.P. Rodrigues
Journal: Journal of Hepatology (2016)
A randomized phase II trial of preoperative chemoradiotherapy with or without cetuximab in locally advanced adenocarcinoma of the rectum.
Authors: A. D. McCollum, D. M. Kocs, P. Chada, D. A. Richards, Y. Wang, K. A. Boehm, L. Asmar, L. Munoz
Journal: Journal of Clinical Oncology (2010)

3635 Background: Preoperative chemoradiation (CRT) is the standard treatment for patients with localized rectal adenocarcinoma. This noncomparative study assessed the toxicity and efficacy of infusional 5-fluorouracil (5-FU]) with or without cetuximab (C) given with pelvic radiotherapy (XRT) as preoperative therapy for patients (pts) with locally advanced adenocarcinoma of the rectum (LAAR). Methods: Pts with newly diagnosed LAAR (AJCC stage II or III) were eligible. Pts were randomized to 2 arms: Arm 1 (standard therapy)—pelvic XRT with a daily fraction schedule to 4,500 cGy (boost 5,040-5,400 cGy) + 5-FU 225 mg/m2/day continuous IV for the duration of XRT. Arm 2—Week 1: C 400 mg/m2; Weeks 2-7: C 250 mg/m2, pelvic XRT and 5-FU as outlined in Arm 1. After 6-8 weeks, pts had definitive surgical resection. Primary objective was pathologic response; other objectives included response based on RECIST (ORR), recurrence-free survival (RFS), overall (OS), local recurrence rates (LR), and toxicity. Tumors are currently being assessed for KRAS gene mutations for correlation with outcomes. Results: 133 pts enrolled (Arm 1 n=66/Arm 2 n=67). Demographics (Arm1/Arm 2): median age 61.7/55.7 years, 68%/61% male, ECOG PS 0, 1 was 64%, 35%/75%, 25% and stage II and III was 61%, 38%/39%, 58%. 74%/73% had surgery; responses were assessed pathologically (TRG score) and radiographically. Results are summarized in the Table. Median OS and RFS have not been reached in either arm. Grade 3-4 toxicities included diarrhea 16/24%, rash 0/10%, mucositis 5/6%, and dehydration 5/6%; 14%/18% pts discontinued due to toxicity and 6%/9% remain on treatment. Conclusions: The addition of cetuximab to standard preoperative CRT for locally advanced rectal cancer was tolerable with manageable toxicity. The pathologic outcomes seem similar to other recent phase II trials, and do not appear different from that achieved with standard 5-FU based CRT. Correlation of outcomes with tumor KRAS is underway. Supported by Bristol-Myers Squibb. Variable Arm 1 (n=49) Arm 2 (n=49) pCR 33% 31% TRG 0 2% 2% 1 14% 6% 2 10% 6% 3 35% 47% 4 33% 31% Most frequent G3-4 toxicities Diarrhea 16% 24% Rash 0% 10% Mucositis 5% 6% Dehydration 5% 6% No significant financial relationships to disclose.
Venous Thromboembolism (VTE) in Patients (pts.) with Monoclonal Gammopathy of Undetermined Significance (MGUS)
Authors: Alaa A Muslimani, Fadi Bailony, Madappa Kundranda, Timothy Spiro, Asif Chaudhry, Harris C Taylor, Ishmael Jaiyesimi, Hamed Daw
Journal: Blood (2008)
Engineering Reversal — Finding an Antidote for Direct Oral Anticoagulants
Authors: Beverley J. Hunt, Marcel Levi
Journal: New England Journal of Medicine (2016)

The need for oral anticoagulation is rising to combat an increasing prevalence of atrial fibrillation and venous thromboembolism in an aging global population. For more than 65 years, only one class of oral anticoagulants filled this role: vitamin K antagonists, which include warfarin and other coumarin derivatives. However, such drugs require monitoring of the international normalized ratio and subsequent dose adjustment owing to their slow onset and offset and unpredictable pharmacokinetics, along with dietary intake of vitamin K, coexisting illnesses, or other medications. These agents are highly effective in reducing thromboembolic complications (including stroke in patients with atrial fibrillation), but . . .
Novel Tumour Suppressor Genes Sorbs3 and Sh2d4a Repress Il-6 Signalling in Hepatocellular Carcinoma
Authors: C. Ploeger, N. Waldburger, A. Fraas, B. Goeppert, S. Pusch, X.W. Wang, P. Schirmacher, S. Roessler
Journal: Journal of Hepatology (2016)
Cost Effectiveness Decision Tree Analysis of Early Versus Late Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM) in the United States (US)
Authors: Shahrukh Hashmi, Chintan Pandya, Morie A Gertz, Angela Dispenzieri, William Hogan, Mustaqeem A Siddiqui, Nandita Khera, Katia Noyes, Shaji K. Kumar
Journal: Blood (2012)
Allogeneic Peripheral Blood Stem Cell Transplants (PBSCT) May Have a Benefit in Acute Lymphoblastic Leukemia (ALL) Outcome.
Authors: Afonso C. Vigorito, Francisco J.P. Aranha, Gislaine B. Oliveira, Kátia A.B. Eid, Roberto Zulli Statistic, Vergilio Colturato, Mair P. De Souza, Fernanda M. Lodi, Henrique Bittencourt, Nelson Castro, José Carlos Barros, Érica R. Pontes, Silvia R. Brandalise, R. DÁlmeida Pereira, A. A. F. Ribeiro, Y. Novis, Nelson Hamerschlak, E. Ferreira, Alexandre M. Azevedo, K. G. De Magalhães, Luiz Fernando Bouzas, Milton A. Ruiz, Angelo Maiolino, Marcio Nucci, Jeferson Ruiz, Ricardo Pasquini, Cármino A. De Souza
Journal: Blood (2005)
P0651 : Clinical outcome and predictor for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients: A prospective observational cohort study
Authors: K.S. Jung, J.Y. Park, Y.E. Chon, H.-S. Kim, W. Kang, S.U. Kim, B.K. Kim, D.Y. Kim, K.-H. Han, S.H. Ahn
Journal: Journal of Hepatology (2015)
APP Gene Is Correlated with C-KIT Mutations and Indicates Poor Disease Outcome in AML1-ETO-Positive Acute Myeloid Leukemia
Authors: Guopan Yu, Ling Jiang, Fan Yi Meng, Changxin Yin, Zhixiang Wang, Hongsheng Zhou, Xuejie Jiang, Qingxiu Zhong, Rui Cao, Libin Liao
Journal: Blood (2014)
Prognostic value of blood neutrophil-to-lymphocyte ratio (NLR)in advanced pancreatic cancer patients treated with Nab-paclitaxel and Gemcitabine: our experience
Authors: B. Savastano, J. Ventriglia, M.M. Laterza, A. Petrillo, G. Tirino, A. Diana, A. Fabozzi, G. Giordano, M. Orditura, F. Ciardiello, F. De Vita
Journal: Annals of Oncology (2015)
Systematic Review of Cases of Transfusion Associated Graft-Versus-Host-Disease (TA-GVHD): Analysis of Patient Characteristics and Outcomes
Authors: Jackie Ostro, Ilana Kopolovic, Yulia Lin, Walter H. Dzik, Christine Cserti, Hideki Tsubota, Amy Keir, Hans A. Messner, Neal DenHollander, Jeannie Callum
Journal: Blood (2014)
Reversibility of Hepatopulmonary Syndrome after Liver Transplantation
Authors: E. Dueñas, R. Rota, J. Ribas, A. Ruiz - Majoral, E. González - Vilatarsana, A. Cachero, A. Amador, C. Baliellas, J. Fabregat, X. Xiol, J. Castellote
Journal: Journal of Hepatology (2016)
Tryptase + SCF + Mast Cell Accumulation in the Human Liver Correlates with Fibrosis in Non-Alcoholic Fatty Liver Disease
Authors: A.C. De La Cruz, A. Omidian, M. Wilson, M. Altintas, N. De La Cruz-Munoz, M. Nadji, M. Garcia-Buitrago, A. Nayer
Journal: Journal of Hepatology (2016)
Deep Sequencing Analysis of Hepatitis B Virus Quasispecies Characteristics in the Pre-S Region Prior to Development of Hepatocellular Carcinoma
Authors: D.K.H. Wong, A.-Y. Zhang, C.-L. Lai, F.-Y. Huang, W.-K. Seto, J. Fung, M.-F. Yuen
Journal: Journal of Hepatology (2016)
Tumor-Associated Circulating Microparticles: A Novel Clinical Tool for Screening and Therapy Monitoring of HCC and other Epithelial Neoplasia
Authors: A. Willms, C. Müller, H. Julich, N. Klein, R. Schwab, I. Richardsen, S. Schaaf, C. Geis, M. Krawczyk, M. Krawczyk, F. Lammert, D. Schuppan, V. Lukacs-Kornek, M. Kornek
Journal: Journal of Hepatology (2016)
Exclusion of Varices Via Transient Elastography Combined with Platelet Count According to the Baveno VI Guidelines can Only be Made for Large not Small Varices
Authors: R. Paternostro, R. Schwarzer, M. Ferlitsch, P. Schwabl, T. Reiberger, M. Mandorfer, M. Peck-Radosavljevic, M. Trauner, A. Ferlitsch
Journal: Journal of Hepatology (2016)
Gemcitabine/docetaxel (GD) vs gemcitabine/cisplatin (GC) in stage IIIB/IV advanced non-small cell lung cancer (NSCLC)
Authors: J. Casal Rubio, S. Vázquez Estevez, F. Vázquez Rivera, M. Amenedo Gancedo, J. Fírvida Pérez, J. Mel Lorenzo, C. Grande Ventura, M. Lázaro Quintela, E. Álvarez Gómez, R. López López
Journal: Journal of Clinical Oncology (2006)

17017 Background: This trial was designed to compare, in terms of response rates, the standard regimen gemcitabine/cisplatin versus a non-platin regimen, gemcitabine-docetaxel in NSCLC. Methods: The chemotherapy regimens administered were: Arm A: gemcitabine 1250 mg/m 2 d1 &amp; 8 plus cisplatin 75 mg/m 2 d1; Arm B: gemcitabine 1000 mg/m 2 d1 &amp; 8 plus docetaxel 85 mg/m 2 d1 repeated every three weeks. Eligibility criteria were measurable stage IV or stage IIIB with pleural effusion NSCLC (brain metastases eligible if asymptomatic) and PS (ECOG Scale) = 0–2. Results: 108 patients (pts) were included between January 2001 and August 2004, 56 in arm A and 52 in arm B. For arm A median age was 59.9 (69.7–50.1); PS 0–1: 83.3%, PS 2: 16.7; Stage IIIB/IV: 18.2/81.8%, For arm B median age was 61.4 (70.4–52.4); PS 0–1: 84%, PS 2: 16%; Stage IIIB/IV: 14/86%. A median number of 5 cycles in arm A and 4 in arm B were administered. Response rates from the 105 eligible patients were: Arm A (55 pts): CR 3.8%, PR 32.1%, SD 32.1%; Arm B (50 pts): CR 2.3%, PR 44.2%, SD 20.9%. Median overall survival (OS) was the same in both arms, 8.9 months (6.3–10.5) in arm A and 8.9 months (3.9–10) in arm B (p = 0.525); median time to progression disease (TTPD) was 6 months (4.2–7.1) in arm A and 5.5 months (4.1–7.2) in arm B (p = 0.607). Toxicities include, in Arms A and B respectively: Grade 3–4 neutropenia 49.1% and 41.2%, with neutropenic fever in 1.8% and 2%; Grade 3/4 thrombocytopenia 30.9/0% and 3.9/0%; Grade 3/4 anemia 14.5/0% and 3.9/0%. Non-hematological toxicity grades 3–4 were similar in both arms, with the exception of nausea and vomiting, (16.3% and 2% in arm A and B respectively); renal and hepatic toxicity (hepatic 5.6% vs. 12.7% and renal 3.7% vs. 0%). Conclusions: The overall response rate was higher in the combination gemcitabine-docetaxel, although there are no significant differences in OS and TTPD. GD is an active non-platin regimen and a good first treatment option for advanced NSCLC. No significant financial relationships to disclose.
Timing of Initiation of Renal Replacement Therapy in Critically Ill Patients With Acute Kidney Injury
Authors: Bruno Adler Maccagnan Pinheiro Besen, Otavio T. Ranzani, Marcelo Park
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 4568: Inhibition of autophagy in EBV-positive Burkitt's lymphoma cells enhances EBV lytic genes expression and replication
Authors: Alessandra De Leo, Francesca Colavita, Fabiola Ciccosanti, Gian Maria Fimia, Paul Lieberman, Elena Mattia
Journal: Cancer Research (2015)

Abstract Autophagy, an important degradation system involved in maintaining cellular homeostasis, serves also to eliminate pathogens and process their fragments for presentation to the immune system. Several viruses have been shown to interact with the host autophagic machinery to suppress or make use of this cellular catabolic pathway to enhance their survival and replication. Epstein Barr virus (EBV) is a γ-herpes virus associated with a number of malignancies of epithelial and lymphoid origin in which establishes a predominantly latent infection. EBV lytic cycle characterized by the sequential expression of immediate early (IE), early and late antigens results in the production of infectious particles which allow the virus to spread. In this study we analyzed the relationship between EBV and autophagy after inducing the virus productive cycle in Burkitt's lymphoma (BL) cells. By monitoring autophagy markers and EBV lytic genes expression, we demonstrate that autophagy is enhanced in the early phases of EBV lytic activation but decreases thereafter concomitantly with increased levels of EBV lytic proteins. In a cell line defective for late antigens expression, we found an inverse correlation between EBV early antigens expression and autophagosomes formation indicating that early after activation, the virus is able to suppress autophagy. We report that inhibition of autophagy by Bafilomycin A1 or shRNA knockdown of beclin1 gene, enhance EBV lytic genes expression as well as intracellular viral DNA and viral progeny yield. Taken together, these findings indicate that viral replication induces an autophagic response which can inhibit the further expression of EBV early lytic products. Moreover, our findings open the possibility to utilize pharmacological modulators of autophagy to control EBV infection and treat EBV-related lymphomas. Citation Format: Alessandra De Leo, Francesca Colavita, Fabiola Ciccosanti, Gian Maria Fimia, Paul Lieberman, Elena Mattia. Inhibition of autophagy in EBV-positive Burkitt's lymphoma cells enhances EBV lytic genes expression and replication. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 4568. doi:10.1158/1538-7445.AM2015-4568
Asthma is associated with reduced fibrinolytic activity, abnormal clot architecture, and decreased clot retraction rate
Authors: M. M. Tomasiak-Lozowska, T. Misztal, T. Rusak, J. Branska-Januszewska, A. Bodzenta-Lukaszyk, M. Tomasiak
Journal: Allergy (2016)

The aim of this study was to assess whether steroid-naïve asthma modulates hemostasis. We evaluated the clot retraction rate (CRR), fibrinolysis rate (FR), clot density (CD) (by confocal microscopy), plasma levels of plasminogen activator inhibitor (PAI-1), and factor XIII (FXIII), NO in exhaled breath (FENO ), spirometry (FEV1 ) and eosinophil count (EOS) in 36 patients with allergic, steroid-naïve asthma and in 34 healthy controls. We observed significantly (P < 0.001) reduced CRR, FR, and FEV1 and increased FENO , EOS, PAI-1, FXIII, and CD in patients with asthma compared with controls. In patients with asthma, FR negatively correlated with CD, FXIII, PAI-1, FENO , and EOS and positively with FEV1 . FXIII positively correlated with CD. Clot retraction rate negatively correlated with FENO and positively with FEV1 (all P < 0.001). These novel findings suggest that asthma itself is associated with decreased CRR and reduced fibrinolytic potential resulting from alterations in clot architecture and elevated levels of plasma FXIII and PAI-1.
Regardless of etiology, progressive renal disease causes ultrastructural and functional alterations of peritubular capillaries
Authors: Janka Bábíčková, Barbara M. Klinkhammer, Eva M. Buhl, Sonja Djudjaj, Mareike Hoss, Felix Heymann, Frank Tacke, Jürgen Floege, Jan U. Becker, Peter Boor
Journal: Kidney International (2016)
In Childhood B-Lineage Acute Lymphoblastic Leukemia (B-ALL) with Hyperdiploidy &gt;50 Chromosomes, Patients with 58 to 66 Chromosomes Have 99% EFS At 6-Year Follow-up: Results of the EORTC CLG 58951 Trial
Authors: Nicole Dastugue, Stefan Suciu, Geneviève Plat, Frank Speleman, Hélène Cavé, Sandrine Girard, Emmanuelle Delabesse, Marie Pierre Pagès, Karima Yakouben, Brigitte Nelken, Francoise Mazingue, Anne Hagemeijer, Anne Uyttebroeck, Carine Gervais, Patrick Lutz, Manuel Teixera, Lucilia Norton, Pierre Heimann, Alina Ferster, Ghislaine Plessis, Patrick Boutard, Marie Agnès Collonge, Pierre Rohrlich, Isabelle Luquet, Martine Munzer, Nicolas Sirvent, Dominique Plantaz, Christian Herens, Claire Hoyoux, Matthias Karrasch, Yves Bertrand, Yves Benoit
Journal: Blood (2011)